In a 36-week placebo-controlled phase 2 trial in patients with non-alcoholic steatohepatitis (NASH), treatment with mgl-3196 (resmetirom) significantly reduces atherogenic lipoprotein particles
1 September 2019 (08:30 - 12:30)
Organised by:
Abstract
About the speaker
Madrigal Pharmaceuticals, Conshohocken (United States of America)
29 More presentations in this session
Access the full session
The Event
ESC Congress 2019
1 September 2019
08:30 CET
